DK0709097T3 - Anti-Fas antistof mod reumatiske sygdomme - Google Patents

Anti-Fas antistof mod reumatiske sygdomme

Info

Publication number
DK0709097T3
DK0709097T3 DK95115210T DK95115210T DK0709097T3 DK 0709097 T3 DK0709097 T3 DK 0709097T3 DK 95115210 T DK95115210 T DK 95115210T DK 95115210 T DK95115210 T DK 95115210T DK 0709097 T3 DK0709097 T3 DK 0709097T3
Authority
DK
Denmark
Prior art keywords
fas
monoclonal antibody
antibody against
rheumatic diseases
fas antibody
Prior art date
Application number
DK95115210T
Other languages
Danish (da)
English (en)
Inventor
Kusiki Nishioka
Shin Yoneyama
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK0709097T3 publication Critical patent/DK0709097T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95115210T 1994-09-27 1995-09-27 Anti-Fas antistof mod reumatiske sygdomme DK0709097T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27013494 1994-09-27

Publications (1)

Publication Number Publication Date
DK0709097T3 true DK0709097T3 (da) 2003-02-24

Family

ID=17482032

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95115210T DK0709097T3 (da) 1994-09-27 1995-09-27 Anti-Fas antistof mod reumatiske sygdomme

Country Status (9)

Country Link
US (1) US6086877A (de)
EP (1) EP0709097B1 (de)
KR (1) KR100371000B1 (de)
AT (1) ATE226447T1 (de)
CA (1) CA2158822C (de)
DE (1) DE69528624T2 (de)
DK (1) DK0709097T3 (de)
ES (1) ES2182860T3 (de)
PT (1) PT709097E (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody
EP1087993B1 (de) 1998-06-18 2008-04-02 Imed Ab Fas peptide und antikörper zur modulierung von apoptosis
HUP0201333A3 (en) 1999-05-24 2004-11-29 Sankyo Company Ltd Chuo Ku Medicinal compositions containing anti-fas antibody
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
JP3898126B2 (ja) 2000-10-24 2007-03-28 俊一 塩澤 慢性関節リウマチに関与するゲノム、その診断方法、その発症可能性の判定方法、それらの検出用診断キットおよび、慢性関節リウマチの治療方法ならびに治療薬剤
US20060104951A1 (en) * 2004-11-16 2006-05-18 Mountz John D Akt and regulation of RA synovial fibroblast apoptosis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
CN102170905B (zh) * 2008-08-01 2016-08-03 阿克西斯股份有限公司 骨关节炎治疗剂及预防剂
US20130011407A1 (en) * 2010-01-29 2013-01-10 Axis Inc. Pharmaceutical composition for treatment or prevention of osteoarthritis, and method of production therefor
US9200077B2 (en) * 2010-01-29 2015-12-01 Axis, Inc. Injectable solution containing therapeutic agent for osteoarthritis
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
DK2802652T3 (da) 2012-01-12 2019-07-15 Endo Global Ventures Clostridium histolyticum enzym
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
AU2018226820B2 (en) 2017-03-01 2022-12-08 Endo Ventures Limited Apparatus and method for assessing and treating cellulite
EP3601556A2 (de) 2017-03-28 2020-02-05 Endo Ventures Limited Verbessertes verfahren zur herstellung von collagenase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201712A (ja) * 1982-05-18 1983-11-24 Green Cross Corp:The 脂肪乳剤
JPS6051105A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The プロスタグランジン脂肪乳剤
JPH02237935A (ja) * 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
WO1991010448A1 (en) * 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
CA2067031C (en) * 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
WO1993000917A1 (en) * 1991-07-05 1993-01-21 Seragen, Inc. Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
US5464833A (en) * 1992-08-19 1995-11-07 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulating composition
EP0723556A4 (de) * 1993-10-14 2003-03-19 Immunex Corp Fas antagonisten und ihre verwendungen
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof

Also Published As

Publication number Publication date
EP0709097A1 (de) 1996-05-01
DE69528624T2 (de) 2003-06-26
US6086877A (en) 2000-07-11
EP0709097B1 (de) 2002-10-23
CA2158822C (en) 2008-12-23
DE69528624D1 (de) 2002-11-28
ES2182860T3 (es) 2003-03-16
CA2158822A1 (en) 1996-03-28
KR960010024A (ko) 1996-04-20
KR100371000B1 (ko) 2003-07-12
PT709097E (pt) 2003-03-31
ATE226447T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
DK0709097T3 (da) Anti-Fas antistof mod reumatiske sygdomme
Verneuil et al. Interstitial granulomatous dermatitis with cutaneous cords and arthritis: a disorder associated with autoantibodies
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
EA200100224A1 (ru) Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0669836T3 (da) Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
MY111518A (en) Absorbent article having enhanced wicking capability
ES2231826T3 (es) Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
DE60238503D1 (de) Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon
DK0678023T3 (da) Anvendelse af riluzol ved fremstilling af lægemidler til behandling af Parkinsons sygdom og parkinsonisme-syndromer
BR0312947A (pt) terapias para insuficiência renal empregando-se interferon-beta
NO882406D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive urinstoff- og karbamat-forbindelser.
DE68920624D1 (de) Menschlicher monoklonaler Antikörper, Hybridoma, das ihn herstellt, und pharmazeutisches Mittel.
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
FI964619A0 (fi) Epilepsialääkkeiden iholle annostelu
SE8804136L (sv) Absorberande engaangsartikel
PT859613E (pt) Utilizacao de flupirtina para a profilaxia e o tratamento de doencas associadas a uma alteracao do sistema celular hematopoietico
EE9900010A (et) T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks
BR0213434A (pt) Método para evitar demência em um paciente, e, uso de rosuvastatina ou seu sal farmaceuticamente aceitável
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
Nallegowda et al. An unusual nail presentation in Marfan's syndrome
Wakabayashi et al. Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study